No Picture
News

Viewpoint: The stakes are high with MassHealth change

Op-ed: April 1 often represents a day of good humor, but April Fools’ Day this year is no laughing matter. On this day, Massachusetts faces a new challenge for maintaining a point of pride for our commonwealth — our No. 1 ranking in the nation for the rate of health… Click here to view original post… […]

No Picture
News

ADDITIONAL DETAILED ANALYSES FROM PHASE 2 STUDY 201 OF LECANEMAB PUBLISHED AS THREE PAPERS IN PEER-REVIEWED JOURNALS

TOKYO and CAMBRIDGE, Mass., March 30, 2023 /PRNewswire/ — Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today that three additional… Click here to view original post… […]

No Picture
News

EISAI PRESENTED NEW ANALYSES OF ARIA AND QOL ON LECANEMAB IN CLARITY AD AT THE AD/PD™ 2023 ANNUAL MEETING

TOKYO and CAMBRIDGE, Mass., March 30, 2023 /PRNewswire/ — Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today that Eisai presented new… Click here to view original post… […]

No Picture
News

Blue Cross Blue Shield of Massachusetts Releases Statement on U.S. District Court Ruling Invalidating Requirement for Free Preventive Services

BOSTON, March 30, 2023 /PRNewswire/ — In response to U.S. District Judge Reed O’Connor’s ruling to invalidate a major provision of the Affordable Care Act (ACA) requiring free preventive care services, Blue Cross Blue Shield of Massachusetts (“BCBSMA”) released the following statement:… Click here to view original post… […]

No Picture
News

NeuroBo Pharmaceuticals Reports Full Year 2022 Financial Results

Company Pipeline to Focus on Cardiometabolic Disease Cash and Cash Equivalents to Fund the Company into 2024 BOSTON, March 30, 2023 /PRNewswire/ — NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company primarily focused on cardiometabolic diseases, today… Click here to view original post… […]

No Picture
News

Massachusetts judge dismisses lawsuit against Biogen over failed launch of Alzheimer’s drug Aduhelm

A Massachusetts federal judge on Wednesday dismissed a class action lawsuit filed by investors against Biogen and several of its current and former executives over the company’s failed Alzheimer’s drug, Aduhelm (aducanumab). The investors argued that Biogen’s contact with the FDA was unlawful and that the company made 25 false… Click here to view original post… […]